Related Experiment Video
Updated: Apr 7, 2026
Author Spotlight: Decoding Mitochondrial Aging
Published on: June 30, 2023
Cdk5-mediated mitochondrial fission: A key player in dopaminergic toxicity in Huntington's disease
Marta Cherubini1, Mar Puigdellívol1, Jordi Alberch1
1Departament de Biologia Cel·lular, Immunologia i Neurociències, Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain.
Abstract:
The molecular mechanisms underlying striatal vulnerability in Huntington's disease (HD) are still unknown. However, growing evidence suggest that mitochondrial dysfunction could play a major role. In searching for a potential link between striatal neurodegeneration and mitochondrial defects we focused on cyclin-dependent kinase 5 (Cdk5). Here, we demonstrate that increased mitochondrial fission in mutant huntingtin striatal cells can be a consequence of Cdk5-mediated alterations in Drp1 subcellular distribution and activity since pharmacological or genetic inhibition of Cdk5 normalizes Drp1 function ameliorating mitochondrial fragmentation. Interestingly, mitochondrial defects in mutant huntingtin striatal cells can be worsened by D1 receptor activation a process also mediated by Cdk5 as down-regulation of Cdk5 activity abrogates the increase in mitochondrial fission, the translocation of Drp1 to the mitochondria and the raise of Drp1 activity induced by dopaminergic stimulation. In sum, we have demonstrated a new role for Cdk5 in HD pathology by mediating dopaminergic neurotoxicity through modulation of Drp1-induced mitochondrial fragmentation, which underscores the relevance for pharmacologic interference of Cdk5 signaling to prevent or ameliorate striatal neurodegeneration in HD.
Insights
Cyclin-dependent kinase 5 (Cdk5) mediates mitochondrial fragmentation in Huntington's disease (HD) striatal cells. Inhibiting Cdk5 may prevent neurodegeneration by normalizing mitochondrial dynamics and reducing dopaminergic toxicity.
Area of Science:
- Neuroscience
- Molecular Biology
- Cell Biology
Background:
- Huntington's disease (HD) involves striatal vulnerability, with mitochondrial dysfunction implicated.
- The precise molecular mechanisms driving this neurodegeneration remain unclear.
- Cyclin-dependent kinase 5 (Cdk5) is investigated as a potential link between mitochondrial defects and HD.
Purpose of the Study:
- To investigate the role of Cdk5 in mitochondrial dysfunction within HD striatal cells.
- To explore the relationship between Cdk5, Drp1, and mitochondrial fission in HD.
- To determine if Cdk5 mediates dopaminergic toxicity in HD.
Main Methods:
- Utilized cell models of mutant huntingtin striatal cells.
- Examined the subcellular distribution and activity of Drp1 (dynamin-related protein 1).
- Employed pharmacological and genetic inhibition of Cdk5.
- Investigated the effects of D1 receptor activation and dopaminergic stimulation.
Main Results:
- Increased mitochondrial fission in HD striatal cells is linked to Cdk5-mediated alterations in Drp1.
- Cdk5 inhibition normalizes Drp1 function and ameliorates mitochondrial fragmentation.
- Dopaminergic stimulation exacerbates mitochondrial defects via Cdk5, increasing Drp1 activity and translocation.
- Cdk5 inhibition abrogates this dopaminergic-induced mitochondrial fragmentation.
Conclusions:
- Cdk5 plays a novel role in HD pathology by mediating dopaminergic neurotoxicity.
- Cdk5 modulates Drp1-induced mitochondrial fragmentation, contributing to striatal neurodegeneration.
- Targeting Cdk5 signaling presents a potential therapeutic strategy for HD.
More Related Videos
06:07Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
Published on: June 23, 2023
15:09The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease
Published on: October 3, 2012
